Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antithrombotics and interventional cardiology].

J P Collet1, G Montalescot

  • 1Service de cardiologie, groupe hospitalier La Pitié-La Salpêtrière, Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mass balance and metabolite profiling of <sup>14</sup>C-Zalunfiban in humans following single-dose subcutaneous administration.

Xenobiotica; the fate of foreign compounds in biological systems·2025
Same author

Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.

NEJM evidence·2025
Same author

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014-2019).

Frontiers in cardiovascular medicine·2023
Same author

Prognostic value of longitudinal strain and ejection fraction in Friedreich's ataxia.

International journal of cardiology·2021
Same author

Unusual arterial thrombotic events in Covid-19 patients.

International journal of cardiology·2020
Same author

Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.

Annales de cardiologie et d'angeiologie·2020
Same journal

Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Alterations in coronary circulation during aortic insufficiency in young subjects.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Cardio-esophageal auscultation.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Hypertensive accidents following the injection of acetylcholine.

Archives des maladies du coeur et des vaisseaux·2010
See all related articles

Angioplasty now uses advanced antithrombotic therapies like abciximab to prevent clots. Future treatments aim for fewer, more effective drugs, balancing efficacy with bleeding risk.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Angioplasty traditionally relied on aspirin and heparin for preventing thrombotic complications.
  • Reopro (abciximab, c7E3) represented a significant therapeutic innovation in antithrombotic therapy.
  • Emerging treatments include low molecular weight heparin for unstable angina.

Purpose of the Study:

  • To review the evolution and impact of antithrombotic therapies in angioplasty.
  • To discuss the efficacy and safety profiles of abciximab and other antithrombotics.
  • To highlight the need for optimized antithrombotic regimens in interventional cardiology.

Main Methods:

  • Review of clinical trial data (EPIC, EPILOG) on abciximab use in coronary syndromes.
  • Analysis of the role of aspirin, heparin, and newer antithrombotic agents.

Related Experiment Videos

  • Evaluation of the risk-benefit ratio of antithrombotic strategies.

    • Main Results:

    • Abciximab demonstrated short- to long-term efficacy in acute and stable coronary syndromes undergoing angioplasty.
    • Low molecular weight heparin shows promise for unstable angina.
    • Increased antithrombotic efficacy correlates with a higher risk of hemorrhage.

    Conclusions:

    • Combination antithrombotic therapy is becoming standard, emphasizing the use of the most effective agents.
    • Future strategies should focus on reducing drug redundancy while managing increased bleeding risks.
    • Comprehensive evaluation of clinical benefits, including ischemic and hemorrhagic events, is crucial for trial assessment.